Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CervoMed Inc. (CRVO : NSDQ)

• Company Description    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $2.66 Daily Weekly Monthly 20 Day Moving Average: 579,525 shares Shares Outstanding: 13.53 (millions) Market Capitalization: $35.98 (millions) Beta: -0.68 52 Week High: $13.13 52 Week Low: $2.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.78% -24.38% 12 Week -28.30% -30.06% Year To Date -66.33% -68.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 Park Plaza Suite 424 Boston - Boston,MA 02216 USA ph: 617-744-4400 fax: 434-220-0722 investors@cervomed.com http://www.cervomed.com

• General Corporate Information    Officers John Alam - Chief Executive Officer; President and Director Joshua S. Boger - Chairman of the Board William Elder - Chief Financial Officer and General Counsel Sylvie Gregoire - Director Jane H. Hollingsworth - Director Peer Information CervoMed Inc. (CORR.) CervoMed Inc. (RSPI) CervoMed Inc. (CGXP) CervoMed Inc. (BGEN) CervoMed Inc. (GTBP) CervoMed Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15713L109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 13.53 Most Recent Split Date: 8.00 (0.67:1) Beta: -0.68 Market Capitalization: $35.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.32 Price/Cash Flow: - Price / Sales: 8.98 EPS Growth vs. Year Ago Period: -53.57% vs. Previous Quarter: 2.27% Sales Growth vs. Year Ago Period: -99.58% vs. Previous Quarter: -97.21% ROE 06/30/26 - - 03/31/26 - -136.08 12/31/25 - -96.04 ROA 06/30/26 - - 03/31/26 - -112.62 12/31/25 - -82.88 Current Ratio 06/30/26 - - 03/31/26 - 3.36 12/31/25 - 4.91 Quick Ratio 06/30/26 - - 03/31/26 - 3.36 12/31/25 - 4.91 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -672.80 Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -672.80 Pre-Tax Margin 06/30/26 - - 03/31/26 - -1,437.13 12/31/25 - -672.97 Book Value 06/30/26 - - 03/31/26 - 1.15 12/31/25 - 1.97 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©